Assignment 3: Literature Review: Five Articles Abstracted onto the Evaluation TableIn Weeks 2–7, you will submit an evaluation table document with five research articles abstracted for your literatu
4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 1/22 Adver Addiction / Volume 111, Issue 12 Review Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta ‐ analysis of safety in the mother, fetus and child Barbara K. Zedler , Ashley L. Mann , Mimi M. Kim , Halle R. Amick , Andrew R. Joyce , E. Lenn Murrelle , Hendrée E. Jones First published: 25 May 2016 https://doi.org/10.1111/add.13462 Cited by: 27 Abstract Aims To assess the safety of buprenorphine compared with methadone to treat pregnant women with opioid use disorder.
Methods We searched PubMed, Embase and the Cochrane Library from inception to February 2015 for randomized controlled trials (RCT) and observational cohort studies (OBS) that compared buprenorphine with methadone for treating opioid ‐ dependent pregnant women.
Two reviewers assessed independently the titles and abstracts of all search results and full texts of potentially eligible studies reporting original data for maternal/fetal/infant death, preterm birth, fetal growth outcomes, fetal/congenital anomalies, fetal/child neurodevelopment and/or maternal adverse events. We ascertained each study's risk of bias using validated instruments and assessed the strength of evidence for each outcome using established methods. We computed eect sizes using random ‐ eects models for each outcome with two or more studies.
Results 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 2/22 Three RCTs ( n = 223) and 15 cohort OBSs ( n = 1923) met inclusion criteria. In meta ‐ analyses using unadjusted data and methadone as comparator, buprenorphine was associated with lower risk of preterm birth [RCT risk ratio (RR) = 0.40, 95% condence interval (CI) = 0.18, 0.91; OBS RR = 0.67, 95% CI = 0.50, 0.90], greater birth weight [RCT weighted mean dierence (WMD) = 277 g, 95% CI = 104, 450; OBS WMD = 265 g, 95% CI = 196, 335] and larger head circumference [RCT WMD = 0.90 cm, 95% CI = 0.14 , 1.66; OBS WMD = 0.68 cm, 95% CI = 0.41, 0.94]. No treatment dierences were observed for spontaneous fetal death, fetal/congenital anomalies and other fetal growth measures, although the power to detect such dierences may be inadequate due to small sample sizes. Conclusions Moderately strong evidence indicates lower risk of preterm birth, greater birth weight and larger head circumference with buprenorphine treatment of maternal opioid use disorder during pregnancy compared with methadone treatment, and no greater harms. Introduction The incidence of prescription and illicit opioid use during pregnancy has increased substantially in the United States since 2000, paralleling a similar escalation in the general population 1. Moreover, the prevalence of opioid use disorder (OUD) during pregnancy more than doubled between 1998 and 2011, to four per 1000 deliveries 2. All pregnancies have a background risk of adverse consequences. Pregnant women with OUD have a higher frequency of additional risk factors for adverse pregnancy outcomes than pregnant women who do not use opioids. These risk factors include chronic viral infections, psychiatric conditions, poor health behaviors, adverse social conditions and inadequate prenatal care 3, 4. Complete opioid abstinence throughout pregnancy is ideal for both mother and fetus, but acute withdrawal during pregnancy is not recommended 5, 6. Relapse rates are high and repeated cycles of intoxication and withdrawal are associated with signicant fetal distress that can lead to placental insuciency and consequent pregnancy loss, intrauterine growth restriction (IUGR) and preterm labor and birth 5, 7-9. The accepted treatment for OUD during pregnancy is long ‐ acting opioid agonist medication ‐ assisted treatment (OMAT), such as methadone (MET) or buprenorphine (BUP), within the context of a comprehensive program of obstetric care and psychosocial interventions 5, 8, 10 -14 . Adequate medication treatment maintains stable opioid blood levels that reduce maternal craving for and use of heroin or other opioids and improves prenatal care and fetal/infant outcomes compared with untreated opioid use or opioid withdrawal 11 , 15 , 16 . MET maintenance treatment during pregnancy has been used widely since the early 1970s via daily visits to government‐ regulated clinics 17 . BUP maintenance treatment has been used increasingly since its approval in France in 1996 and the About Sections PDF Tools Share 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 3/22 United States in 2002, partly because of its availability in the private practitioner setting and pharmacology that enables less than daily dosing, lower overdose risk and fewer drug interactions 11 , 18 . Three RCTs have been conducted comparing BUP and MET as OMAT in pregnancy, with a primary focus on multiple measures of neonatal abstinence syndrome (NAS) 19 -21 . Previous systematic reviews and meta ‐ analyses of these RCTs 5, 22 concluded that BUP and MET have similar ecacy for reducing pregnant women's opioid use but that neither opioid agonist was superior for all maternal, fetal and child outcomes 11 . However, uncertainty was high regarding the conclusions due to the small body of evidence, particularly for outcomes other than NAS, due largely to their infrequency. For NAS, the meta‐ analyses identied no dierence between BUP and MET in the frequency of NAS requiring treatment, the amount of morphine or time required to treat or the length of hospitalization. However, the single, large RCT ( n = 131) 19 observed signicantly less severe NAS, based on 89% less morphine required to treat and 43% shorter hospitalization, compared with no dierence in the two small RCTs (n = 14 20 and n = 21 21 ). No additional RCTs are available or likely to be performed, but the cumulative body of relevant observational studies has not been reviewed rigorously or synthesized quantitatively for any pregnancy outcomes. The objectives of this review were to assess systematically all available evidence from clinical studies regarding the safety of buprenorphine compared with methadone treatment of opioid ‐ dependent pregnant women and provide quantitative treatment eect estimates for selected pregnancy outcomes, as feasible.
Methods The conduct and reporting of this review conform with the Preferred Reporting Items for Systematic Reviews and Meta ‐ Analyses (PRISMA) statement (Supporting information, Figure S1 ) 23 . Search strategy and inclusion criteria We searched the PubMed and Embase databases and the Cochrane Database of Systematic Reviews from their inception through February 2015 using the search strategy in Supporting information, Table S1 without language restrictions. We searched manually the reference lists of review papers and the included studies to identify additional papers. We included studies if they: (1) were RCTs or observational (cohort or case–control) studies (OBSs); (2) enrolled opioid‐ dependent pregnant women; (3) compared buprenorphine or buprenorphine–naloxone with methadone as OMAT; and (4) reported original data on one or more specied pregnancy‐ related outcomes representing important potential pregnancy‐ related harms (Table 1). This review focused on outcomes other than NAS for practical reasons. There are several pregnancy outcomes besides NAS which lack systematic review or meta ‐ analysis to date and, due to its numerous measures, NAS would benet from a separate 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 4/22 systematic review that includes eligible OBSs. Two researchers reviewed each title and abstract independently and then assessed the full texts of potentially eligible papers. Disagreements between reviewers regarding eligibility were resolved by consensus.
Table 1. Inclusion criteria and outcome denitions. Study component Criterion/denition Population Opioid ‐ dependent pregnant women Intervention Buprenorphine prescribed as opioid agonist medication ‐ assisted treatment for opioid use disorder Comparator Methadone prescribed as opioid agonist medication‐ assisted treatment for opioid use disorder Outcomes Spontaneous fetal death Miscarriage (death of a fetus or embryo at or before 20 completed weeks gestation) Stillbirth (death of a fetus after 20 completed weeks gestation) All fetal death Spontaneous fetal death plus induced fetal death (induced abortion) Preterm birth Live birth before 37 completed weeks gestation Fetal growth outcomes *Birth weight (g) Converted to grams as necessary *Low birth weight (LBW) < 2500 g regardless of gestational age *Small for gestational age (SGA) Birth weight below an established sex ‐ and gestational week ‐ specic mean value *Intrauterine growth restriction (IUGR) Diminished growth velocity documented in two or more intrauterine growth assessments *Head circumference at birth (cm) Converted to centimeters as necessary Fetal/congenital anomalies An abnormality of structure (malformation), function or metabolism present at birth or identied at fetal death; birth defects Sudden infant death syndrome (SIDS) Unanticipated and unexplained death of a live‐ born infant before age 1 year a b c 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 5/22 Study component Criterion/denition Fetal/child neurodevelopment Cognitive, behavioral, sensory, motor or functional development. Abnormal is a delay or impairment Maternal adverse events during pregnancy Categorized by each study as serious (e.g. death) or non ‐ serious Study designs Randomized controlled trials, observational (cohort or case–control) studies EGA = estimated gestational age.
a We included one study that treated women with an abuse ‐ deterrent combination buprenorphine (BUP)–naloxone formulation 44 , but excluded it from quantitative analyses. b Preterm birth was dened as < 36 completed weeks gestation in Colo mbini 2008 37 . c SGA was dened as birth weight below: (a) 2 standard deviations from the sex ‐ and gestational‐ week specic mean value (Jones 2010 19 ; Kakko 2008 39 ); (b) 10th percentile of the sex‐ and gestational ‐ week specic mean value (Siedentopf 2004 47 ); or (c) the 5th percentile of the sex‐ and gestational ‐ week specic mean value (Brulet 2007 36 ; Meyer 2015 43 ). d Maternal adverse events were dened as: (a) medical events (Lacroix 2011 41 ); (b) complications (Prasad 2013 44 ); or (c) any untoward medical occurrence (Jones 2010 19 ). Data extraction and risk of bias assessment Two researchers extracted data independently from each included paper into standardized tables and resolved discrepancies by consensus. A senior researcher conrmed the accuracy of entries. We contacted authors as feasible if additional information was needed. We categorized studies as RCT or OBS based on elements as reported. Two researchers assessed the risk of bias (ROB) independently for each outcome as high, medium or low, and a senior researcher resolved any conicts. For RCTs, we assessed randomization adequacy, allocation concealment, missing outcome data, selective outcome reporting and blinding of participants, study personnel and assessors according to standards of the US Agency for Healthcare Research and Quality (AHRQ) 24 . For OBSs, we evaluated the selection of participants, comparability of cohorts, exposure and outcome assessment and follow ‐ up adequacy using the Newcastle– Ottawa Scale as expanded by Guyatt 25 , 26 . Data synthesis and statistical analyses The unit of analysis was pregnancies or live births, depending on the outcome. We conducted meta‐ analyses of the unadjusted study data using random eects models (DerSimonian & d 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 6/22 Laird method) 27 to account for heterogeneity among the studies and estimated unadjusted treatment eects as weighted mean dierences (WMDs) for continuous outcomes and risk ratios (RRs) for binary outcomes. Statistical signicance was dened as a 95% condence interval (CI) for the pooled eect that did not include zero for WMDs or 1.0 for RRs. We anticipated a substantial amount of missing outcome data from attrition based upon the challenges of research with opioid ‐ dependent people, especially during pregnancy 19 , 28 , 29 . We decided a priori to include only unadjusted outcome data as available from studies with low or medium ROB in our main analyses. To examine the stability of the main estimates, we conducted sensitivity analyses by including high ROB studies or imputing missing binary data under best‐ and worst ‐ case scenarios 28 , 29 . We combined OBSs with similar study methods and clinical variability 30 and calculated summary treatment eect estimates separately by study design 28 , 29 . We estimated inconsistency (heterogeneity) across studies using the I statistic 28 and investigated sources of clinical and/or methodological variation when we suspected heterogeneity that might aect the results 31 . We synthesized outcome data qualitatively when studies were too heterogeneous to pool quantitatively or when only a single study reported an outcome. For comparisons with 10 or more studies we inspected funnel plots to assess potential publication bias 32 . Analyses were conducted using Comprehensive Meta‐ Analysis, version 3.2 (Biostat; Englewood, NJ, USA). Rating strength of evidence (SOE) SOE is a summary of condence in our ndings. We evaluated the SOE for each outcome based on guidance established by AHRQ using ve domains: study limitations, directness, consistency, precision and reporting bias 33 . The assigned grade (high, moderate, low, insucient) represents the degree of condence in the eect estimates for an outcome. We graded SOE separately for the bodies of evidence from RCTs and OBSs. 2 Results Of 1111 citations identied, 140 full ‐ text papers were assessed for eligibility, and 18 studies 18 - 21 , 34 -49 (reported in 23 papers 18 -21 , 34 -52 ) satised our inclusion criteria (Fig. 1). The only three RCTs 19 -21 (six papers 19 -21 , 50 -52 ) that have been conducted to date were included (223 participants; published 2005–10) (Supporting information, Table S2 ). Fifteen OBSs 18 , 34 - 39 , 41 -48 (17 papers) 18 , 34 -49 enrolled a total of 1923 participants in prospective 18 , 34 -39 , 41 , 42 , 45 -47 (n = 12) or retrospective 43 , 44 , 48 (n = 3) cohort studies published 2001–15. No case– control studies were identied. The abuse ‐ deterrent combination BUP–naloxone formulation is prescribed increasingly as OMAT, particularly in the United States and Australia 53 , 54 . We included one study that treated women with BUP–naloxone 44 , but considered it too clinically dierent from the other studies to include in quantitative analyses. However, sensitivity analyses indicated that eect estimates did not dier for any outcome, whether the BUP– naloxone study was included or excluded. Sample sizes were 15–609. Attrition ranged from 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 7/22 22% 20 to 33% 19 overall in the RCTs and was unbalanced between treatment groups in two RCTs 19 , 20 . The range of estimated gestational age at study enrollment was 6–37 weeks. The mother's average daily dose at delivery ranged from 5.1 to 18.7 mg for BUP and 35–99.4 mg for MET. Outcome denitions among the studies were generally consistent, except for maternal adverse events (AEs) and small for gestational age (SGA) (Table 1). Statistical heterogeneity was low among the main analyses except for growth outcomes [birth weight (two RCTs, I = 50%); LBW (two OBSs, I = 62%); and SGA (two OBSs, I = 50%)]. ROB was rated medium for each RCT (n = 3, Supporting information, Table S3 ) and medium ( n = 9) 18 , 38 -43 , 48 , 49 or high ( n = 8) 34 - 37 , 44 -47 for all OBSs (Supporting information, Table S4 ). Twelve OBSs assessed the balance between treatment groups for various confounding factors at study enrollment (Supporting information, Table S2 ), but only two OBSs adjusted for confounding factors in estimating treatment eects 39 , 48 . If not provided through an integrated, comprehensive prenatal addiction treatment program, MET was generally administered by standalone clinics or pharmacies while BUP was provided by oce ‐ based practitioners. Visual inspection of the funnel plot for preterm birth revealed no evidence of publication bias (Supporting information, Figure S2 ); no other outcomes had enough studies to yield a reliable funnel plot. 2 2 2 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 8/22 Figure 1 Open in gure viewer PowerPoint Flow of paper disposition and study selection Caption Spontaneous fetal death 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 9/22 Among the seven studies 19 -21 , 35 , 38 , 39 , 41 that assessed spontaneous fetal death, ve medium ROB studies reported at least one (Supporting information, Table S5 ). The dierence in treatment eect between BUP and MET was not signicant from two RCTs 19 , 20 and three OBSs 38 , 39 , 41 (Table 2 and Fig. 2a), but the direction diered by study design. The risk estimate did not change in sensitivity analyses that included all fetal deaths (spontaneous deaths and elective terminations) or imputed missing pregnancy outcomes. Figure 2 Open in gure viewer PowerPoint (a) Spontaneous fetal death; (b) fetal/congenital anomalies associated with buprenorphine compared with methadone 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 10/22 Caption Fetal/congenital anomalies Nine studies 19 , 21 , 34 , 38 , 39 , 41 , 43 , 46 , 48 that evaluated malformations or other defects at birth or pregnancy loss identied chromosomal defects and cardiovascular, central nervous system, craniofacial and musculoskeletal malformations (Supporting information, Table S7 ). Only two studies treated essentially all women with MET from preconception to end of pregnancy 41 , 48 . Among the medium ROB RCT 19 and four OBSs 38 , 41 , 43 , 48 that reported at least one defect, the treatment eect was not signicantly dierent in magnitude or direction between BUP and MET (Table 2 and Fig. 2b). Table 2. Summary of ndings and strength of evidence for buprenorphine compared with methadone treatment of opioid use disorder during pregnancy. Outcome No. of studies (n pregnancies or live births) Summary eect size (95% CI) Strength of evidence grade Spontaneous fetal death RCT 2 (187) RR = 0.26 (0.03–2.31) Low Observational 3 (271) RR = 1.17 (0.32–4.27) Low Fetal/congenital anomalies RCT 1 (131) RR = 0.42 (0.02–10.08) Insucient Observational 4 (933) RR = 1.18 (0.39–3.62) Low Preterm birth RCT 3 (166) RR = 0.40 (0.18–0.91) Low Observational 7 (1343) RR = 0.67 (0.50–0.90) Moderate Birth weight, g RCT 2 (150) WMD = 324 (32–617) Low Observational 6 (1085) WMD = 265 (196–335) Moderate a a a b c d 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 11/22 Outcome No. of studies (n pregnancies or live births) Summary eect size (95% CI) Strength of evidence grade Low birth weight Observational 2 (222) 0.51 (0.17–1.59) Low Small for gestational age RCT 1 (131) RR = 0.63 (0.06–6.77) Insucient Observational 2 (692) RR = 0.67 (0.34–1.31) Low Intrauterine growth restriction Observational 2 (385) RR = 0.80 (0.57–1.12) Low Head circumference, cm RCT 2 (150) WMD = 0.90 (0.14–1.66) Low Observational 5 (960) WMD = 0.68 (0.41–0.94) Moderate Sudden infant death syndrome (SIDS) Observational 1 (83) 0% BUP versus 6% MET ( P = 0.19) Insucient Neurodevelopment (fetal and child) *Fetal heart rate and motor activity suppression (third trimester): BUP < MET ( P < 0.05) RCT 1 (175) *Visual selective attention at 4 months of age:
no signicant dierence BUP versus MET Insucient Observational 2 (198) *Visual latency at 52 months of age: BUP < MET (prolonged) ( P = 0.02) Insucient Non ‐ serious maternal adverse events RCT 1 (175) 77% BUP versus 93% MET ( P = 0.003) Insucient e e e 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 12/22 Outcome No. of studies (n pregnancies or live births) Summary eect size (95% CI) Strength of evidence grade Serious maternal adverse events RCT 1 (175) 9% BUP versus 16% MET ( P = 0.19) Insucient Maternal death 0 (0) NA Insucient BUP = buprenorphine; MET = methadone; NA = not applicable; WMD = weighted mean dierence; RCT = randomized controlled trial; CI = condence interval; RR = relative risk. a Includes only studies with low or medium risk of bias and cases with an outcome available.
b Based on assessment of ve domains: study limitations (risk of bias), consistency, directness, precision and reporting bias (Berkman 2013 33 ). See Supporting information, Table S6 for denitions and the full ndings. c A relative risk of 0.40 would result in 120 fewer premature infants per 1000 births in BUP ‐ treated pregnant women compared with MET ‐ treated women. See Fig. 3 for details. d A relative risk of 0.67 would result in 49 fewer premature infants per 1000 births in BUP‐ treated pregnant women compared with MET ‐ treated women. See Fig. 3 for details. e Preliminary evidence: the clinical signicance of these ndings is unknown. Preterm birth Seventeen studies 18 -21 , 34 -39 , 41 -45 , 47 , 48 reported preterm births. The eect estimate from three RCTs 19 -21 indicated lower risk of preterm birth for BUP compared with MET. Similarly, the treatment eect among seven medium ROB OBSs 18 , 38 , 39 , 41 -43 , 48 showed that BUP was associated with a decreased risk of preterm birth compared with MET (Table 2 and Fig. 3). The treatment eect was similar in sensitivity analyses that included six OBSs with high ROB 34 -37 , 45 , 47 (including one that dened preterm birth as before 36 weeks gestation) 37 or imputed missing data. 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 13/22 Figure 3 Open in gure viewer PowerPoint Preterm birth associated with buprenorphine compared with methadone Caption Infant growth outcomes Eight of 14 studies 19 , 21 , 39 , 41 -43 , 48 , 49 reporting birth weight had medium ROB. In two RCTs 19 , 21 BUP ‐ exposed neonates averaged 324 g heavier than MET ‐ exposed neonates. In six OBSs 39 , 41 -43 , 48 , 49 the mean dierence was 265 g (Table 2 and Fig. 4a). Results were similar in sensitivity analyses that included four high ROB studies 35 , 37 , 45 , 47 . The treatment eect 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 14/22 attenuated and was non ‐ signicant in two OBS that adjusted for gestational age at birth 39 or maternal age, cigarette smoking, polysubstance use, OMAT dose and duration of dependence 48 . Preterm births in the studies included in the birth weight meta ‐ analysis ranged from 0 to 19% in the two RCTs (0 and 7% for BUP; 9 and 19% for MET) and 4–19% among the ve OBSs (4–19% for BUP; 8–17% for MET). One OBS excluded preterm births from the birth weight analysis 49 . Figure 4 Open in gure viewer PowerPoint (a) Birth weight; (b) head circumference associated with buprenorphine compared with methadone Caption 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 15/22 Head circumference was similarly signicantly larger in infants born to BUP ‐ treated than MET‐ treated women among seven medium ROB studies 19 , 21 , 39 , 42 , 43 , 48 , 49 . In two RCTs 19 , 21 , BUP‐ exposed newborns' heads averaged 0.90 cm larger than MET ‐ exposed newborns. In ve OBSs 39 , 42 , 43 , 48 , 49 , mean head circumference was 0.68 cm larger in BUP ‐ than MET ‐ exposed infants (Table 2 and Fig. 4b). The treatment eect did not dier after adjustment for a number of factors (excluding gestational age) in one OBS 48 . Conversely, the risk of low birth weight (< 2500 g) did not dier signicantly between BUP and MET exposure in two medium ROB OBSs 39 , 48 (Table 2 and Fig. 5a), nor did the risk of being SGA in two medium ROB OBSs 39 , 43 (Table 2 and Fig. 5b). The eect estimate was similar when two high ROB studies 36 , 47 were included. One RCT 19 observed SGA in 2% of BUP ‐ exposed and 3% of MET‐ exposed infants, a non ‐ signicant dierence. The RR for IUGR from two medium ROB OBSs 18 , 41 was 0.80 (Table 2 and Fig. 5c) and did not change appreciably when a high ROB cohort study 35 was included. 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 16/22 Figure 5 Open in gure viewer PowerPoint (a) Low birth weight; (b) small for gestational age; (c) intrauterine growth restriction associated with buprenorphine compared with methadone 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 17/22 Caption Sudden infant death syndrome One medium ROB OBS ( n = 83) 39 observed that no infants exposed to BUP in utero experienced sudden infant death syndrome (SIDS) within 4 months of birth compared with two of 36 exposed to MET (5.6%), a non‐ signicant dierence (Table 2). One death occurred in a 5‐ week old male born at 38 weeks and treated for NAS. The MET‐ treated mother was HIV ‐ positive and smoked 10–15 cigarettes daily. The other death was an 8‐ week old female delivered at 38 weeks via caesarean section for IUGR and treated for NAS. The eect estimate was similar when a high ROB OBS 46 was included. Fetal/child neurodevelopment As gestation progresses, coupling of fetal movement and heart rate increases, reecting coordination of autonomical and somatic nervous systems and general fetal wellbeing 55 . Neurobehavior can be monitored non ‐ invasively with non ‐ stress testing (NST) that assesses heart rate variability and associated fetal movement. A high ROB substudy of a RCT assessed maternal blood levels and NST after daily dosing of OMAT during the third trimester 51 . Peak OMAT blood levels were associated with signicantly less suppression of fetal heart rate variability and movement and more favorably reactive NSTs in BUP ‐ versus MET‐ treated women (Supporting information, Table S8 ). Another RCT substudy found similar dierential treatment ‐ related eects on heart rate and movement in the early versus late third trimester 50 . Two medium ROB cohort studies assessed visual development in infants and children exposed prenatally to OMAT (Supporting information, Table S8 ). One found no signicant dierence in visual selective attention among 31 children of mothers treated with BUP versus MET 40 . The second study found signicantly prolonged visual latency in 22 infants of MET ‐ treated mothers compared with 30 infants of BUP‐ treated mothers 49 . Adverse eects Three included studies reported non ‐ fatal maternal AEs 19 , 41 , 44 (Supporting information, Table S9 ), while none reported any maternal deaths. One RCT ( n = 175) 19 assessed AEs weekly and graded them as serious or non ‐ serious. The RCT observed a lower risk of non‐ serious AEs in BUP‐ treated women but no dierence in the risk of serious AEs. Two high ROB OBSs that did not describe how AEs were collected or assessed had disparate ndings. One study ( n = 90) 44 reporting selected AEs that are typically considered serious found no signicant treatment ‐ related dierence for BUP–naloxone versus MET. The other study ( n = 135) 41 reported all AEs and found an increased risk of AEs overall for BUP. 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 18/22 Discussion We synthesized the evidence from three RCTs and 15 OBSs that compared buprenorphine and methadone treatment of pregnant women with OUD. We calculated treatment ‐ related risk estimates for eight pregnancy‐ related outcomes, including four without previous published meta‐ analysis. Our work conrms and extends previous treatment risk estimates from limited RCT evidence by also synthesizing the available, larger body of observational study evidence. Consistent with previous RCT ‐ based meta ‐ analyses 5, 22 , we identied no statistically or clinically signicant dierence between BUP and MET in the risk estimates for spontaneous fetal death among the OBSs and across all studies. However, the paucity of events and small sample sizes limited the precision of estimates, ability to stratify by early versus late pregnancy losses and the condence in our estimates of the relationship between fetal death and OMAT. The overall frequency of spontaneous fetal deaths in women with OUD among both study types was substantially lower than the estimated 15–20% in the general population. Further, most occurred after the rst trimester, in contrast to three ‐ fourths of spontaneous losses during the rst trimester in the general population 56 , 57 . This apparent underestimate is probably related to a delay by many opioid‐ dependent pregnant women in seeking prenatal care until after completing the high‐ risk rst trimester 35 , 58 , 59 and insucient reporting of time of enrollment in several studies 36 , 37 , 44 -46 . Our ability to assess the relationship between fetal death and OMAT was also limited substantially, given sparse and inconsistent patient‐ level reporting of gestational timing (onset and duration) of BUP or MET treatment and important potential confounders 60 , 61 . We found no dierence in the risk of fetal/congenital anomalies by maternal treatment. The frequency and type of reported anomalies were broadly similar to what would be expected in the general population, with no particular patterns noted by treatment group. However, most studies characterized the reported defects poorly and failed to collect or describe relevant confounders adequately or even details of exposure to the opioid agonist, particularly during the critical rst trimester. Moreover, no included study was powered to detect an increase in specic congenital anomalies, which occur rarely ( ≤ 1/1000 births ), and sparse events and exposed pregnancies limited the precision of estimates. In addition, defects not readily apparent at birth may be under‐ ascertained, as no studies evaluating congenital anomalies followed infants through the entire rst year. Therefore, we have limited condence in our eect estimates. The risk of preterm birth was lower in BUP ‐ exposed infants compared with MET ‐ exposed infants. The risk reduction found was consistent between study types and with a previous meta‐ analysis of the same RCTs examined in the present analysis 5. However, potentially confounding inuences were not reported or adjusted for in any treatment eect estimates. Notwithstanding these limitations, we have moderate condence in our ndings. 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 19/22 Unadjusted birth weight and head circumference were signicantly greater in infants of BUP ‐ treated mothers compared with MET ‐ treated mothers. The ndings were consistent between study designs and with previous meta ‐ analyses 5, 22 . We have moderate condence in these treatment estimates, but adequate adjustment of confounding factors, particularly gestational age, and larger sample sizes would probably provide more stable and valid estimates of treatment eect. A very small body of observational studies showed no association between prenatal BUP or MET and LBW, IUGR or SGA. The sparse body of evidence limits condence in the LBW, SGA and IUGR ndings. Fetal growth and birth parameters are inuenced by sex, gestational age, multi ‐ fetal pregnancy, maternal cigarette smoking and use of other substances, and placental and anatomical factors 62 . Studies in this review were inconsistent in describing whether they included multi‐ fetal pregnancies and preterm births (both tend to be smaller) in analyses of growth parameters. Multi‐ fetal pregnancies were infrequent and unlikely to signicantly impact eect estimates dierentially. However, failure to adjust for gestational age or exclude preterm births from growth parameter analyses may overestimate the eects of maternal BUP treatment due to BUP's associated signicantly lower risk of preterm birth. We were unable to explore fully this confounding eect without patient ‐ level data. Aggregated source data for birth weight and head circumference also limited the clinical interpretation of treatment eect estimates because established norms, and thus minimally important dierences, are sex‐ and gestational age‐ dependent 63 . Data from three small studies provided preliminary and insucient evidence that maternal BUP treatment may be associated with more favorable fetal neurobehavior than MET treatment. The developing fetal nervous system appeared more vulnerable to opioid ‐ related suppression earlier versus later in pregnancy with signicantly less suppression of fetal heart rate and movement by BUP compared with MET, at least transiently at peak maternal exposure associated with once‐ daily dosing 64 . Split‐ dose administration of MET has been associated with less fetal suppression 65 . One medium ROB RCT that collected and analyzed maternal AEs systematically found signicantly fewer non ‐ serious AEs but no dierence in serious AEs among BUP ‐ treated women versus MET‐ treated women. Dierential cardiovascular eects are plausible due to the established risk of QT ‐ interval prolongation and serious arrhythmia associated with MET 66 , 67 . Two high ROB OBSs with poorly characterized methods of collecting and analyzing AEs had discordant ndings. In one study, with signicantly more AEs in BUP ‐ treated women, the cohorts were comparable for several confounders but the MET‐ treated women had more frequent study visits (a confounding co‐ intervention) 41 . The evidence regarding AEs is insucient to draw a clinically meaningful conclusion in either direction. Future studies should collect and analyze treatment‐ associated AEs during pregnancy in a systematic and standardized fashion and use an established system to code and analyze AEs descriptively 68 . 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 20/22 A strength of this review is the inclusion of all available evidence regarding opioid agonist treatment during pregnancy, including data from well ‐ conducted observational cohort studies 69 -71 . Previous published systematic reviews and meta‐ analyses included only three RCTs, with a total combined sample size of 223 drawn from seven university treatment centers in the United States and Austria. The addition of 1923 participants in 15 cohort studies conducted in six additional countries and among a wider range of clinical settings increased the precision, statistical power and generalizability of our ndings. Furthermore, most outcomes examined were largely objective, documented routinely in clinical obstetric practice and thus less prone to detection bias from measurement error and lack of blinding. Concordance between the treatment‐ related risk estimates from both the RCTs and OBSs bolstered condence in the strength of the evidence for spontaneous fetal death, fetal/congenital anomalies, preterm birth, birth weight, head circumference and SGA. The main limitations were the uneven quality of the studies and limited number of events and sample sizes, potentially providing low statistical power to detect between ‐ group dierences. RCTs provide the most consistent and unbiased estimates of treatment eects, but high‐ quality RCTs often are not available, particularly in vulnerable populations such as the one under study 68 , 69 . The complexities of both OUD and pregnancy present daunting challenges in the design, recruitment and conduct of rigorous clinical studies. Moreover, RCTs are generally not designed with sucient sample size (especially for rare outcomes such as fetal death and congenital anomalies), follow ‐ up duration or population variability for results generalizable to the population at large. The RCTs included in this review were conducted rigorously, but suered from relatively high levels of overall and dierential attrition that increased the risk of selection bias and were not accounted for optimally in the published analyses 28 , 70 Twelve of the 15 observational studies assessed baseline comparability of the cohorts for a few confounders or co‐ interventions but did not adjust eect estimates for imbalances. For example, many studies did not assess, report or adjust for concomitant substance use during pregnancy as evaluated by urine toxicology or self ‐ report. Information on substance use would inform the interpretation of the OMAT‐ related eects in terms of possible dierences between the study participants.
Finally, maternal AEs and fetal/congenital anomalies (and, to a lesser extent, SGA) were dened inconsistently or ascertained among the studies that reported them, increasing clinical heterogeneity and limiting the opportunity to pool results among studies. In clinical studies, AEs are often not collected, analyzed or reported in a standardized and systematic fashion 68 . Conclusion BUP treatment of maternal opioid use disorder during pregnancy was not associated with greater harms than MET treatment, and moderately strong evidence indicated lower risk of preterm birth, greater birth weight and larger head circumference with BUP. Our results conrm and extend previous RCT evidence and further inform benet/risk assessment in 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 21/22 Supporting Information References Citing Literature clinical decision ‐ making regarding treatment of pregnant women with OUD, although evidence is currently insucient to establish superior safety of either opioid agonist during pregnancy for all maternal, fetal and child outcomes examined.
Declaration of interests Partial funding for this review was provided by Indivior PLC (formerly Reckitt Benckiser Pharmaceuticals) to Venebio Group, LLC. The review was conceived, designed, executed and reported by the authors, who had sole control over the literature selected, data analysis, interpretation and manuscript preparation. Indivior PLC was asked to review the nal manuscript for proprietary information. The opinions and conclusions of the authors are their own and do not necessarily reect the position of Indivior. At the time the work was conducted, B.K.Z., A.L.M., M.M.K., H.R.A., A.R.J. and E.L.M. were paid consultants of Venebio Group, LLC, which has had research and consulting agreements with Indivior PLC. H.E.J. has no nancial ties to either Indivior PLC or Venebio Group, LLC, and did not receive any form of remuneration in the preparation or writing of this paper. All authors report no other potential conicts of interest with the gaming, pharmaceutical, alcohol or tobacco industries. Acknowledgements The authors wish to thank Drs Georgiy Bobashev, Dale Glasser, and Pradeep Rajan for helpful comments on drafts of the text, Dr Laura Morgan for contributions to the assessment of study quality and preparation of forest plots and Dr Pradeep Rajan and Molly Ronayne Sherwood for assistance in the literature search. About Wiley Online Library Help & Support 4/26/2018 Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta‐ analysis of sa … https://onlinelibrary.wiley.com/doi/full/10.1 111/add.13462 22/22 Opportunities Connect with Wiley Copyright © 1999-2018 John Wiley & Sons, Inc . All rights reserved